Key Inclusion Criteria:

          1. Adult patients ≥18 years of age (or the legal age of adults to consent to participate
             in a clinical study per country specific regulations).

          2. Has histologically confirmed recurrent or metastatic HPV16 positive squamous cell
             cervical cancer, who have experienced disease progression after treatment with
             platinum containing therapy as defined in the protocol

          3. Patient must be determined to be positive for HPV16 genotype, as determined by a
             specified central reference laboratory.

          4. Patient must have measurable disease as defined by RECIST 1.1.

          5. Must have received prior bevacizumab and taxol unless meets pre-specified protocol
             criteria

          6. ECOG performance status of 0 or 1.

          7. Has adequate organ and bone marrow function as defined in the protocol.

          8. Anticipated life expectancy ≥20 weeks.

        Key Exclusion Criteria:

          1. Prior treatment with an agent that blocks the PD-1/PD-L1 pathway.

          2. Prior treatment with other systemic immune-modulating agents as defined in the
             protocol

          3. Major surgery or radiation therapy within 14 days of first administration of study
             drug

          4. Has received treatment with an approved systemic therapy within 4 weeks of first dose
             of study drug, or has not yet recovered (ie, grade ≤1 or baseline) from any acute
             toxicities except for laboratory changes as described in the protocol

          5. Has another malignancy that is progressing or requires active treatment and/or history
             of malignancy other than cervical cancer within 3 years of date of first planned dose
             of study drug as defined in the protocol

          6. Has any condition that requires ongoing/continuous corticosteroid therapy (>10 mg
             prednisone/day or anti-inflammatory equivalent) within 4 weeks prior to the first dose
             of study drug. 7. Has ongoing or recent (within 5 years) evidence of significant
             autoimmune disease that required treatment with systemic immunosuppressive treatments
             as defined in the protocol

        NOTE: Other protocol-defined Inclusion/ Exclusion criteria apply